Use of A2A adenosine receptor agonists

摘要

The present invention relates to methods for producing coronary vasodilation with little peripheral vasodilation by administering doses of a pharmaceutical composition including regadenoson, named (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide, - an adenosine A2A receptor agonist - to a human in an amount sufficient to increase the average coronary peak flow velocity by at least about 16.5 cm/sec.